Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: Yahoo! Finance
of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago. Presentation Details Abstract: 2664 Title: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114 (formerly SRF114) in Patients with Advanced Solid Tumors. Poster Session– Developmental Therapeutics - Immunotherapy Date and Time: Saturday, June 1, 2024, 9:00 a.m. – 12:00 p.m. Central Daylight Time About CHS-114 CHS-114, a human, afucosylated anti-CCR8 monoclonal antibody, is designed to selectively target human CCR8 and preferentially deplete CCR8+ regulatory T cells (Tregs) within the tumor microenvironment, not effector T (Teff) cells in tumors or Tregs in normal tissue. In preclinical studies, CHS-114 induced antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) to de
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024GlobeNewswire
- Drug Delivery Technologies market is projected to grow at a CAGR of 5.5% by 2034: Visiongain [Yahoo! Finance]Yahoo! Finance
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years [Yahoo! Finance]Yahoo! Finance
- Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
CHRS
Earnings
- 3/13/24 - Miss
CHRS
Analyst Actions
- 3/18/24 - HC Wainwright
CHRS
Sec Filings
- 4/15/24 - Form ARS
- 4/15/24 - Form DEFA14A
- 4/15/24 - Form DEF
- CHRS's page on the SEC website